A biotechnology company dedicated to repurposing drugs and developing supplements to address unmet needs in a variety of medical areas. The COVID-19 pandemic made apparent the gaps in our therapeutic arsenal that KARE Biosciences aims to strengthen. The company is currently working on a multivitamin (KidneyVite) to meet all the nutritional needs of kidney patients, and a drug (Ramatroban) to treat COVID-19, sickle cell disease, cardiovascular disease, neurological diseases, obesity and more.
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
ClinicalTrials.gov Identifier: NCT05706454